This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2021 Feb 18;137(7):861-862.

doi: 10.1182/blood.2020009781.

Building on BTK inhibition in MCL

Kami Maddocks¹

Affiliations

PMID: 33599764
DOI: 10.1182/blood.2020009781

Free article

Editorial

Building on BTK inhibition in MCL

Kami Maddocks. Blood. 2021.

Free article

. 2021 Feb 18;137(7):861-862.

doi: 10.1182/blood.2020009781.

Author

Kami Maddocks¹

Affiliation

¹ The Ohio State University.

PMID: 33599764
DOI: 10.1182/blood.2020009781

No abstract available

PubMed Disclaimer

Comment on

Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial.
Le Gouill S, Morschhauser F, Chiron D, Bouabdallah K, Cartron G, Casasnovas O, Bodet-Milin C, Ragot S, Bossard C, Nadal N, Herbaux C, Tessoulin B, Tchernonog E, Rossi C, McCulloch R, Gastinne T, Callanan MB, Rule S. Le Gouill S, et al. Blood. 2021 Feb 18;137(7):877-887. doi: 10.1182/blood.2020008727. Blood. 2021. PMID: 33181832 Clinical Trial.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Silverchair Information Systems
Other Literature Sources
- scite Smart Citations